NCT01527487已完成2 期
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 76
- 试验地点
- 15
- 主要终点
- Pathologic Complete Response (pCR) Rate in Patients Treated With ErC for 6 Cycles Prior to Surgery
研究概览
简要总结
The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced HER2-negative breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed invasive adenocarcinoma of the breast.
- •Primary palpable disease confined to the breast and axilla on physical examination (clinical Stage II or III disease). For patients without clinically suspicious axillary adenopathy, the primary must be >2 cm in diameter by physical examination or imaging studies (clinical T2-3, N0-2, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). Patients who have had axillary node dissection and have pN3a (i.e. ≥10 involved axillary nodes) are also eligible.
- •Patients entering the trial after undergoing an axillary node dissection will be eligible if they meet other entry criteria.
- •Estrogen receptor (ER) and progesterone receptor (PR) status in the primary tumor known or pending at the time of study registration.
- •Resolution of all acute effects of surgical procedures to ≤ grade
- •For patients who had or will have, a sentinel node and/or axillary node dissection, completion at least 1 week prior to the initiation of study treatment with a well-healed wound is required.
- •Bilateral, synchronous breast cancer is allowed if both primary tumors are HER2-negative and at least one meets the specified qualifying tumor or nodal inclusion criteria.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-
- •Patients entering this study must be willing to provide release of tumor tissue collected at baseline during a diagnostic procedure if available, and at the time of future surgical procedure(s) for correlative testing. If tissue is not available, the patient will still be eligible for enrollment to the study.
- •No evidence of metastatic disease, as documented by complete staging workup ≤8 weeks prior to initiation of study treatment.
- •No prior treatment for this breast cancer with the exception of criterion #
- •HER2-negative tumor status defined as:
- •Immunohistochemical (IHC) 0-1+ or
- •IHC 2+ or IHC 3+ confirmed as FISH (Fluorescence in situ hybridization) or SISH (Silver in situ hybridization) negative (defined by ratio <2.2)
- •Adequate hematologic function defined as:
- •Absolute neutrophil count (ANC) ≥1500/μL
- •Hemoglobin (Hgb) ≥10 g/dL
- •Platelets ≥100,000/uL
- •Adequate liver function defined as:
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x the upper limit of normal (ULN)
- •Total bilirubin ≤ the institutional ULN
- •Adequate renal function defined as:
- •Serum creatinine ≤1.5 mg/dL x ULN OR calculated creatinine clearance ≥50 mL/min by the Cockcroft-Gault method:
- •GRF =(140-age) x (weight/kg) x (0.85 if female) (72 x serum creatinine mg/dL)
- •Other laboratory testing:
- •Serum magnesium ≥ the institutional lower limit of normal (LLN)
- •Serum potassium ≥the institutional LLN
- •Female and ≥18 years of age.
- •Negative serum pregnancy test within <7 days prior to initial trial treatment.
- •Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures that are approved by their study physician while receiving study treatment and continuing for 3 weeks after the last dose of study drug treatment, who are not breastfeeding, and who have a negative serum pregnancy test prior to start of dosing.
- •Willingness and ability to comply with trial and follow-up procedures.
- •Ability to understand the nature of this trial and give written informed consent.
排除标准
- •Clinical T4 lesions, including inflammatory breast cancer. Clinical N3 involvement (e.g., ipsilateral, infraclavicular, supraclavicular, and internal mammary nodes).
- •Peripheral neuropathy (motor or sensory) > grade 1 according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).
- •Patient has received radiotherapy for treatment of previous cancer that included ≥30% of major bone marrow containing areas (e.g., pelvis, lumbar, spine).
- •Known or suspected allergy or hypersensitivity to any of the study drugs (i.e., eribulin, cyclophosphamide, docetaxel) or known hypersensitivity to polysorbate
- •Patients with acute or chronic liver or renal disease or pancreatitis.
- •Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV).
- •Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Patients must have discontinued use of such agents prior to beginning study treatment. However, use of GNRH agonists for the purpose of fertility preservation or suppression of heavy menses is permitted (see Section 5.4.1).
- •Patient has any of the following cardiac diseases currently or within the last 6 months:
- •Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
- •Heart rate-corrected QT interval (QTc) > 480 ms on screening electrocardiogram (ECG) (using Bazett's formula)
- •Unstable angina pectoris
- •Congestive heart failure (New York Heart Association [NYHA] ≥ Grade 2
- •Acute myocardial infarction
- •Conduction abnormality not controlled with pacemaker or medication
- •Significant ventricular or supraventricular arrhythmias (Patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible).
- •Valvular disease with significant compromise in cardiac function
- •Chronic use of drugs that cause QTc prolongation. Patients must discontinue use of these drugs 7 days prior to the start of study treatment.
- •Presence of other active cancers, or history of treatment for invasive cancer ≤5 years. Patients with stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
- •Patients may not receive any other investigational or anti-cancer treatments while participating in this trial.
- •Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- •Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
研究组 & 干预措施
Eribulin+Cyclophosphamide (ErC)
Experimental
Eribulin (Er): 1.4mg/m2 IV (Days 1 and 8) given short (≤1.5 minutes) IV infusion, per institutional standard
Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard
干预措施: Eribulin (Drug)
Eribulin+Cyclophosphamide (ErC)
Experimental
Eribulin (Er): 1.4mg/m2 IV (Days 1 and 8) given short (≤1.5 minutes) IV infusion, per institutional standard
Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard
干预措施: Cyclophosphamide (Drug)
Docetaxel+Cyclophosphamide (TC)
Experimental
Docetaxel (T): 75 mg/m2 IV (Day 1), given by 1-hour IV infusion
Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard
干预措施: Cyclophosphamide (Drug)
Docetaxel+Cyclophosphamide (TC)
Experimental
Docetaxel (T): 75 mg/m2 IV (Day 1), given by 1-hour IV infusion
Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard
干预措施: Docetaxel (Drug)
结局指标
主要结局
Pathologic Complete Response (pCR) Rate in Patients Treated With ErC for 6 Cycles Prior to Surgery
时间窗: 18 weeks
One cycle = 21 days. Pathologic CR is defined as the absence of invasive tumor in the breast and lymph node tissue removed at the time of definitive surgery as judged by the local pathologist.
次要结局
- The Number of Adverse Events as a Measure of Safety and Tolerability.(43 months)
- Clinical Response Rate (cRR) of ErC as Neoadjuvant Therapy(43 months)
- Disease-Free Survival (DFS) at 2 Years(24 months)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
2 期
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)Relapsed/Refractory RhabdomyosarcomaNon-rhabdomyosarcoma Soft Tissue SarcomaEwing SarcomaNCT03441360Eisai Inc.23
已完成
1 期
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast PatientsBreast CancerNCT01795586H. Lee Moffitt Cancer Center and Research Institute19
已完成
1 期
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid TumorsRelapsed Solid TumorsRefractory Solid TumorsNCT02596503University of Colorado, Denver2
已完成
2 期
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2Breast CancerNCT01593020M.D. Anderson Cancer Center54
已完成
1 期
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor MalignanciesMalignant Solid TumourBreast Cancer Nos Metastatic RecurrentNeuropathyNCT01554371University of California, San Francisco44